Oryzon Genomics - IND granted for collaborative Phase II trial
Oryzon Genomics announced that it has received FDA investigational new drug (IND) approval for the initiation of a collaborative Phase II trial...
107 Views
Oryzon Genomics - Clinical ramp in Q3; several catalysts approaching
Oryzon Genomics reported Q322 results that are largely in line with our expectations. The clinical ramp up of its key assets, iadademstat and...
370 Views
Oryzon Genomics - Encouraging safety data in PORTICO
Oryzon Genomics has announced promising preliminary blinded aggregate safety data from its ongoing Phase IIb PORTICO trial at the 10th European...
806 Views
Oryzon Genomics - Preclinical collaboration in orphan disease
Oryzon Genomics has announced that it is has entered into a partnership with the Charcot-Marie-Tooth Research Foundation (CMTRF). The collaboration...
855 Views
Oryzon Genomics - Costs up but company remains well funded
Oryzon Genomics has reported results for H122 and highlighted the progress of key assets iadademstat and vafidemstat during the period. It reported...
749 Views